In the study presented here the authors documented 50 patients with chronic glaucoma, aged between 42 and 86, who were followed up on an outpatient basis for a minimum of 3 and a maximum of 6 years. The results can be summarized as follows: 1) treatment with timolol resulted in an average lowering of intraocular pressure by 6 mm Hg, without any fall-off in effect over several years; 2) there was no deterioration in visual fields or visual acuity during treatment with timolol, and in some cases there was an improvement; 3) in the cases of angle-closure glaucoma the therapy was combined with pilocarpine; this resulted in a greater lowering of pressure than that achieved by treatment with timolol alone in cases of open-angle glaucoma.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/s-2008-1050452 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Evaluation, Diagnosis, and Management of Infantile Hemangiomas-A Comprehensive Review.
J Clin Med
January 2025
Department of Pediatric Surgery, Children's Hospital Zagreb, Ulica Vjekoslava Klaića 16, 10000 Zagreb, Croatia.
Infantile hemangioma (IH) is the most common pediatric benign vascular tumor. Its pathogenesis is still poorly understood, and it usually appears during the first few weeks of life and follows a characteristic natural course of proliferation and involution. Most IHs are small, benign, resolve spontaneously, and do not require active treatment but only active observation.
View Article and Find Full Text PDFThe timing and safety of topical timolol treatment for superficial infantile hemangioma: a retrospective cohort study.
Eur J Pediatr
January 2025
Department of Pediatric Surgery, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Unlabelled: Numerous studies have shown that topical timolol is effective in treating infantile hemangioma (IH) with minimal adverse events. However, consensus is lacking on optimal timing, dosage, frequency, and safety parameters for this treatment. This study aims to explore the timing and safety of topical timolol treatment for superficial IH.
View Article and Find Full Text PDFEfficacy and safety of preservative-free anti-glaucomatous eye drops (dorzolamide/timolol) in ocular hypertension and/or glaucoma.
Int Ophthalmol
January 2025
Chairman and Professor of Ophthalmology, Kasr Alainy Faculty of Medicine, Cairo University, Giza, Egypt.
Purpose: This study evaluated the efficacy, safety, and tolerability of a single-dose, preservative-free (PF) Dorzolamide/Timolol combination (Twinzol-SDU).
Methods: A 3-month single-arm, multicenter, prospective cohort study was conducted in Egypt between January 2021 and October 2022 on previously diagnosed and controlled patients with ocular hypertension and/or glaucoma. Efficacy was assessed using the change in intraocular pressure (IOP) after 6 and 12 weeks.
Radius-Maumenee syndrome (idiopathic dilated episcleral vessels).
GMS Ophthalmol Cases
December 2024
Universidade Federal do Paraná (UFPR), Curitiba, Brazil.
Purpose: Idiopathic elevated episcleral venous pressure (IEEVP) or Radius-Maumenee syndrome (RMS) is a rare disease without any identified underlying cause. An increasing episcleral venous pressure (EVP) leads to raised intraocular pressure (IOP) and consequently glaucomatous damage of the optic nerve. The objective of this paper is to report this rare condition as well as its clinical management.
View Article and Find Full Text PDFColloid-Forming Prodrug-Hydrogel Composite Prolongs Lower Intraocular Pressure in Rodent Eyes after Subconjunctival Injection.
Adv Mater
January 2025
Department of Chemical Engineering & Applied Chemistry, University of Toronto, 200 College Street, Toronto, ON, M5S 3E5, Canada.
Colloidal drug aggregates (CDAs) are challenging in drug discovery due to their unpredictable formation and interference with screening assays. These limitations are turned into a strategic advantage by leveraging CDAs as a drug delivery platform. This study explores the deliberate formation and stabilization of CDAs for local ocular drug delivery, using a modified smallmolecule glaucoma drug.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!